Associate Professor of Neurology, Massachusetts General Hospital
Neurology
Dr. Michael A. Schwarzschild, MD
|
|
Give Review
Michael A. Schwarzschild, MD works in the field of Neurology. He studied medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Michael Schwarzschild is a published doctor. He has 101 papers published. The most current publication "Neuroprotection by caffeine in the MPTP model of Parkinson's disease and its dependence on adenosine A2A receptors." Michael Schwarzschild accepts Medicare.
Publications
- Prospective study of plasma urate and risk of Parkinson Disease in men and women.
- Neuroprotection by caffeine in the MPTP model of Parkinson's Disease and its dependence on adenosine A2A receptors.
- Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's Disease.
- Urate and neuroprotection trials.
- A Prospective Analysis of Airborne Metal Exposures and Risk of Parkinson Disease in the Nurses Health Study Cohort.
- Protection by inosine in a cellular model of Parkinson's Disease.
- Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson׳s Disease.
- Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not α-Synuclein-Induced Neuronal Cell Loss.
- Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial.
- Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders.
- Caffeine consumption and risk of dyskinesia in CALM-PD.
- Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.
- Linked clinical trials - the development of new clinical learning studies in Parkinson's Disease using screening of multiple prospective new treatments.
- Dopamine transporter imaging is associated with long-term outcomes in Parkinson's Disease.
- Caffeine and risk of Parkinson's Disease in a large cohort of men and women.
- Urate in Parkinson's Disease: more than a biomarker?
- Caffeine in Parkinson Disease: Better for cruise control than snooze patrol?
- Alcohol and risk of Parkinson's Disease in a large, prospective cohort of men and women.
- Protection of dopaminergic cells by urate requires its accumulation in astrocytes.
- Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection.
- Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's Disease.
- Obesity, diabetes, and risk of Parkinson's Disease.
- Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study.
- A prospective study of bowel movement frequency and risk of Parkinson's Disease.
- Preclinical jockeying on the translational track of adenosine A2A receptors.
- Use of ibuprofen and risk of Parkinson Disease.
- The delayed-start study in Parkinson Disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
- Restless legs syndrome and Parkinson's Disease in men.
- Plasma urate and Parkinson's Disease in women.
- Calcium channel blocker use and risk of Parkinson's Disease.
- Prenatal and early life factors and risk of Parkinson's Disease.
- Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.
- Rasagiline in Parkinson's Disease.
- Restless legs Syndrome and erectile dysfunction.
- Reproductive factors, exogenous estrogen use, and risk of Parkinson's Disease.
- Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson Disease.
- Obesity and restless legs Syndrome in men and women.
- Smoking and Parkinson's Disease: using parental smoking as a proxy to explore causality.
- Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine.
- Genetic determinants of hair color and Parkinson's Disease risk.
- Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's Disease.
- Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart.
- Diet, urate, and Parkinson's Disease risk in men.
- Perceived imbalance and risk of Parkinson's Disease.
- Telomere length and risk of Parkinson's Disease.
- Recreational physical activity and risk of Parkinson's Disease.
- Peripheral inflammatory biomarkers and risk of Parkinson's Disease.
- Erectile function and risk of Parkinson's Disease.
- Prospective study of dietary pattern and risk of Parkinson Disease.
- Consumption of dairy products and risk of Parkinson's Disease.
- Molecular markers of early Parkinson's Disease based on gene expression in blood.
- Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
- Pesticide exposure and risk for Parkinson's Disease.
- Survival of Parkinson's Disease patients in a large prospective cohort of male health professionals.
- A prospective study of night shift work, sleep duration, and risk of Parkinson's Disease.
- Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's Disease.
- Nonsteroidal antiinflammatory drug use and the risk for Parkinson's Disease.
- Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice.
- Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum.
- Folate intake and risk of Parkinson's Disease.
- Obesity and the risk of Parkinson's Disease.
- Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
- Sleep regulation in adenosine A2A receptor-deficient mice.
- Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's Disease.
- Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
- Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's Disease.
- Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.
- Nonsteroidal anti-inflammatory drugs and the risk of Parkinson Disease.
- Alcohol consumption and the incidence of Parkinson's Disease.
- Prospective study of phobic anxiety and risk of Parkinson's Disease.
- Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization.
- Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
- DARPP chocolate: a caffeinated morsel of striatal signaling.
- 8-(3-Chlorostyryl)caffeine may attenuate MPTP neuroToxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.
- Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin.
- Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors.
- Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
- Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
- Clinical trials for neuroprotection in Parkinson''s Disease: overcoming angst and futility?
- Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma.
- Novel pharmacological targets for the treatment of Parkinson''s Disease.
- Targeting adenosine A2A receptors in Parkinson''s Disease.
- Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis.
- Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulatio...
- Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine.
- Adenosine A2A receptor antagonists for Parkinson''s Disease: rationale, therapeutic potential and clinical experience.
- Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia.
- (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B.
- Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
- A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization.
- Physical activity and the risk of Parkinson Disease.
- Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses.
- Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS.
- Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.
- A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's Disease.
- Caffeine''s neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Toxicity shows no tolerance to chronic caffeine administration in mice.
- Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons.
- A(2A) adenosine receptor deficiency attenuates brain injury induced by Transient focal ischemia in mice.
- Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
- Caffeine, postmenopausal estrogen, and risk of Parkinson's Disease.
Schools
Harvard Medical School
Brigham and Women39s Hospital
Mass General Hospital
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Cerebrovascular Disease
- Concussion
- View All
Doctors Specialties
- Neurology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Harvard Pilgrim Health Care PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Education
-
Massachusetts General Hospital -
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1821088337 | |
| NPPES Provider LastName | SCHWARZSCHILD | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 021143117 | |
| NPPES Provider State | MA | |
| Specialty Description | Neurology | |
| Total Claim Count | 396.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1821088337 |
| Last Name Of The Provider | SCHWARZSCHILD |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. John R. Sims, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah Dodwell, MD |
|
|
Dr. Andrew W. Tarulli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yoon Cho, MD |
|
|
Dr. Rebecca Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eugenia S. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marie H. Saint-Hilaire, MD
This Doctor is OpenDoctor Recommended.
|